Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease
- PMID: 10683287
- DOI: 10.1006/exnr.1999.7245
Effect of acute L-Dopa pretreatment on apomorphine-induced rotational behavior in a rat model of Parkinson's disease
Abstract
Currently, reduction of apomorphine-induced rotational behavior in the 6-hydroxydopamine (6-OHDA) lesioned rat is the most utilized drug-induced paradigm for assessing functional efficacy in a rat model of Parkinson's disease (PD). Any clinically predictive animal model of PD should include a positive response to l-dopa, the standard pharmacotherapy for PD. However, the acute interaction between L-dopa and apomorphine has never been studied to determine if L-dopa pretreatment could reduce apomorphine-induced rotational behavior in a 6-OHDA lesioned rat. The present study was designed to explore whether, indeed, pretreatment with subrotational doses of L-dopa could inhibit apomorphine-induced rotations. The data indicate that L-dopa significantly reduced apomorphine-induced rotational behavior only at one dose (5.0 mg/kg) for 12 min. Based on these and other data, it is concluded that although the apomorphine-induced rotational paradigm may continue to be utilized as one additional indicator of efficacy in the 6-OHDA rat model of PD, it is not in itself a completely valid functional assay.
Copyright 2000 Academic Press.
Similar articles
-
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.Exp Neurol. 1998 Jun;151(2):334-42. doi: 10.1006/exnr.1998.6819. Exp Neurol. 1998. PMID: 9628768
-
The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.Brain Res Bull. 2011 Nov 25;86(5-6):367-72. doi: 10.1016/j.brainresbull.2011.09.016. Epub 2011 Sep 24. Brain Res Bull. 2011. PMID: 21963945
-
Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.Basic Clin Pharmacol Toxicol. 2008 Mar;102(3):300-7. doi: 10.1111/j.1742-7843.2007.00153.x. Epub 2007 Oct 31. Basic Clin Pharmacol Toxicol. 2008. PMID: 17973898
-
Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.Pol J Pharmacol Pharm. 1976;28(5):469-93. Pol J Pharmacol Pharm. 1976. PMID: 796834 Review. No abstract available.
-
The pharmacology of Parkinson's disease: basic aspects and recent advances.Experientia. 1984 Nov 15;40(11):1165-72. doi: 10.1007/BF01946641. Experientia. 1984. PMID: 6437857 Review.
Cited by
-
Neuroprotective Properties of a Standardized Extract from Myracrodruon urundeuva Fr. All. (Aroeira-Do-Sertão), as Evaluated by a Parkinson's Disease Model in Rats.Parkinsons Dis. 2014;2014:519615. doi: 10.1155/2014/519615. Epub 2014 Jun 25. Parkinsons Dis. 2014. PMID: 25061534 Free PMC article.
-
Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer.Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4708-13. doi: 10.1073/pnas.062047599. Epub 2002 Mar 26. Proc Natl Acad Sci U S A. 2002. PMID: 11917105 Free PMC article.
-
Proteomic approach to studying Parkinson's disease.Mol Neurobiol. 2004 Jun;29(3):271-88. doi: 10.1385/MN:29:3:271. Mol Neurobiol. 2004. PMID: 15181239 Review.
-
The role of autophagy dysregulation in manganese-induced dopaminergic neurodegeneration.Neurotox Res. 2013 Nov;24(4):478-90. doi: 10.1007/s12640-013-9392-5. Epub 2013 Apr 19. Neurotox Res. 2013. PMID: 23604964 Free PMC article.
-
Preventive Effect of Two New Neurotensin Analogues on Parkinson's Disease Rat Model.J Mol Neurosci. 2018 Dec;66(4):552-560. doi: 10.1007/s12031-018-1171-6. Epub 2018 Oct 30. J Mol Neurosci. 2018. PMID: 30374780
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources